These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 149988)

  • 1. Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity.
    Zabik JE; Levine RM; Maickel RP
    Pharmacol Biochem Behav; 1978 Apr; 8(4):429-35. PubMed ID: 149988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activity of enantiomers of amphetamine in rats.
    Maickel RP; Light KE; Zabik JE
    Neuropharmacology; 1982 Dec; 21(12):1323-7. PubMed ID: 6218425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of D-amphetamine and L-amphetamine in reversing depression of mouse locomotor activity caused by reserpine.
    Proctor CD; Kirby J; Wood MH; Wade LH; King PK
    Arch Int Pharmacodyn Ther; 1974 Nov; 212(1):108-15. PubMed ID: 4451411
    [No Abstract]   [Full Text] [Related]  

  • 4. Yohimbine: behavioral and biochemical effects in mice.
    Sanghvi I; Gershon S
    Arch Int Pharmacodyn Ther; 1974 Jul; 210(1):108-20. PubMed ID: 4280277
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine.
    Breese GR; Cooper BR; Mueller RA
    Br J Pharmacol; 1974 Oct; 52(2):307-314. PubMed ID: 4155993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disulfiram and the drug-induced effects on motility.
    Maj J; Przegaliński E; Wielosz M
    J Pharm Pharmacol; 1968 Mar; 20(3):247-8. PubMed ID: 4385060
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanism of the protective effect of reserpine on aggregated mice treated with (+)-amphetamine.
    Menon MK; Dandiya PC
    J Pharm Pharmacol; 1967 Sep; 19(9):596-602. PubMed ID: 4383144
    [No Abstract]   [Full Text] [Related]  

  • 8. An inhibitory role for brain serotonin-containing systems in the locomotor effects of d-amphetamine.
    Hollister AS; Breese GR; Kuhn CM; Cooper BR; Schanberg SM
    J Pharmacol Exp Ther; 1976 Jul; 198(1):12-22. PubMed ID: 132524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular infusion of norepinephrine and amphetamine: direct versus indirect action.
    Segal DS; McAllister C; Geyer MA
    Pharmacol Biochem Behav; 1974; 2(1):79-86. PubMed ID: 4857225
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of CNS catecholamine-depleting drugs on dextroamphetamine-induced elevation of halothane MAC.
    Johnston RR; Way WL; Miller RD
    Anesthesiology; 1974 Jul; 41(1):57-61. PubMed ID: 4275974
    [No Abstract]   [Full Text] [Related]  

  • 11. Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate.
    Finn IB; Iuvone PM; Holtzman SG
    Neuropharmacology; 1990 Jul; 29(7):625-31. PubMed ID: 1974712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of pentylenetetrazol and trimethadione on the metabolism of serotonin in brain and its relation to the anticonvulsant action of trimethadione.
    Diaz PM
    Neuropharmacology; 1974 Jul; 13(7):615-21. PubMed ID: 4280025
    [No Abstract]   [Full Text] [Related]  

  • 13. Reserpine-induced alterations in brain amines and their relationship to changes in the incidence of minimal electroshock seizures in mice.
    Azzaro AJ; Wenger GR; Craig CR; Stitzel RE
    J Pharmacol Exp Ther; 1972 Mar; 180(3):558-68. PubMed ID: 4258979
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of tyrosine hydroxylase and dopamine-beta-hydroxylase inhibition with the effects of various 6-hydroxydopamine treatments on d-amphetamine induced motor activity.
    Hollister AS; Breese GR; Cooper BR
    Psychopharmacologia; 1974 Mar; 36(1):1-16. PubMed ID: 4151923
    [No Abstract]   [Full Text] [Related]  

  • 15. Neurochemical changes following the administration of depleters of biogenic monoamines.
    Lane JD; Smith JE; Shea PA; McBride WJ
    Life Sci; 1976 Dec; 19(11):1663-7. PubMed ID: 12434
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship of biogenic amines to behavior.
    Breese GR; Cooper BR; Hollister AS
    J Psychiatr Res; 1974; 11():125-33. PubMed ID: 4282384
    [No Abstract]   [Full Text] [Related]  

  • 17. Differentiaton of neuropharmacological actions of apomorphine and d-amphetamine.
    Quock RM; Horita A
    Pharmacol Biochem Behav; 1976 Dec; 5(6):627-31. PubMed ID: 139615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential behavioral responses of spontaneously hypertensive (SHR) and normotensive (WKY) rats to d-amphetamine.
    McCarty R; Chiueh CC; Kopin IJ
    Pharmacol Biochem Behav; 1980 Jan; 12(1):53-9. PubMed ID: 6445066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2,5-Dimethoxy-4-methylamphetamine (DOM), a neuropharmacological examination.
    Wallach MB; Friedman E; Gershon S
    J Pharmacol Exp Ther; 1972 Jul; 182(1):145-54. PubMed ID: 4261221
    [No Abstract]   [Full Text] [Related]  

  • 20. Trace amines inhibit the electrically evoked release of [3H]acetylcholine from slices of rat striatum in the presence of pargyline: similarities between beta-phenylethylamine and amphetamine.
    Baud P; Arbilla S; Cantrill RC; Scatton B; Langer SZ
    J Pharmacol Exp Ther; 1985 Oct; 235(1):220-9. PubMed ID: 3930699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.